T-cell receptor profiling in cancer

被引:111
作者
Kirsch, Ilan [1 ]
Vignali, Marissa [1 ]
Robins, Harlan [1 ,2 ]
机构
[1] Adapt Biotechnol, Seattle, WA USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
关键词
Immunosequencing; Ig/TCR sequence biomarkers; Lymphoid clonality assessment/tracking; MINIMAL RESIDUAL DISEASE; REPERTOIRE; THERAPY; PCR;
D O I
10.1016/j.molonc.2015.09.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunosequencing is a platform technology that allows the enumeration, specification and quantification of each and every B- and/or T-cell in any biologic sample of interest. Thus, it provides an assessment of the level and distribution of all the clonal lymphocytes in any sample, and allows "tracking" of a single clone or multiple clones of interest over time or from tissue to tissue within a given patient. It is based on bias-controlled multiplex PCR and high-throughput sequencing, and it is highly accurate, standardized, and sensitive. In this review, we provide evidence that immunosequencing is becoming an important analytic tool for the emerging field of immune-oncology, and describe several applications of this approach, including the assessment of residual disease post therapy in lymphoid malignancies, the prediction of response to immunotherapeutics of solid tumors containing tumor infiltrating lymphocytes, the identification of clonal responses in vaccination, infectious disease, bone marrow reconstitution, and autoimmunity, and the exploration of whether there are population-based stereotyped responses to certain exposures or interventions. (C) 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:2063 / 2070
页数:8
相关论文
共 35 条
[11]   High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer [J].
Emerson, Ryan O. ;
Sherwood, Anna M. ;
Rieder, Mark J. ;
Guenthoer, Jamie ;
Williamson, David W. ;
Carlson, Christopher S. ;
Drescher, Charles W. ;
Tewari, Muneesh ;
Bielas, Jason H. ;
Robins, Harlan S. .
JOURNAL OF PATHOLOGY, 2013, 231 (04) :433-440
[12]   Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies [J].
Gill, Saar ;
June, Carl H. .
IMMUNOLOGICAL REVIEWS, 2015, 263 (01) :68-89
[13]  
Gros A, 2014, J CLIN INVEST, V124, P2246, DOI [10.1172/JC173639, 10.1172/JCI73639]
[14]  
Howie B., 2015, SCI TRANSL MED, V7, p301ra131
[15]  
Kirsch I.R., 2015, SCI TRANSL IN PRESS
[16]   Estimating hypermutation rates from clonal tree data [J].
Kleinstein, SH ;
Louzoun, Y ;
Shlomchik, MJ .
JOURNAL OF IMMUNOLOGY, 2003, 171 (09) :4639-4649
[17]   Combining Next-Generation Sequencing and Immune Assays: A Novel Method for Identification of Antigen-Specific T Cells [J].
Klinger, Mark ;
Kong, Katherine ;
Moorhead, Martin ;
Weng, Li ;
Zheng, Jianbiao ;
Faham, Malek .
PLOS ONE, 2013, 8 (09)
[18]   IMMUNOGLOBULIN GENE REARRANGEMENT AND CELL-SURFACE ANTIGEN EXPRESSION IN ACUTE LYMPHOCYTIC LEUKEMIAS OF T-CELL AND B-CELL PRECURSOR ORIGINS [J].
KORSMEYER, SJ ;
ARNOLD, A ;
BAKHSHI, A ;
RAVETCH, JV ;
SIEBENLIST, U ;
HIETER, PA ;
SHARROW, SO ;
LEBIEN, TW ;
KERSEY, JH ;
POPLACK, DG ;
LEDER, P ;
WALDMANN, TA .
JOURNAL OF CLINICAL INVESTIGATION, 1983, 71 (02) :301-313
[19]   Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders [J].
Ladetto, M. ;
Brueggemann, M. ;
Monitillo, L. ;
Ferrero, S. ;
Pepin, F. ;
Drandi, D. ;
Barbero, D. ;
Palumbo, A. ;
Passera, R. ;
Boccadoro, M. ;
Ritgen, M. ;
Goekbuget, N. ;
Zheng, J. ;
Carlton, V. ;
Trautmann, H. ;
Faham, M. ;
Pott, C. .
LEUKEMIA, 2014, 28 (06) :1299-1307
[20]   Antibody-modified T cells: CARs take the front seat for hematologic malignancies [J].
Maus, Marcela V. ;
Grupp, Stephan A. ;
Porter, David L. ;
June, Carl H. .
BLOOD, 2014, 123 (17) :2625-2635